logo
Share SHARE
FONT-SIZE Plus   Neg

Amgen Blood Cancer Drug Meets Primary Endpoint In Late-Stage Study

Amgen Inc. (AMGN) Monday said its blood cancer drug Kyprolis in combination with two other drugs helped patients live significantly longer compared to standard treatment.

The California-based drug giant said patients with relapsed multiple myeloma when treated with Kyprolis in combination with Revlimid and low-dose dexamethasone lived 8.7 months longer without disease worsening compared to patients treated with only Revlimid and low-dose dexamethasone.

Multiple myeloma is the second most common hematologic cancer that results from an abnormality of plasma cells, usually in the bone marrow. In the US, about 70,000 people are living with multiple myeloma and around 24,000 new cases are diagnosed annually.

The FDA had granted accelerated approval of Kyprolis for the treatment of patients with multiple myeloma in 2012. Kyprolis is marketed in the US by Amgen's subsidiary Onyx Pharmaceuticals Inc.

The study called Aspire was conducted on 792 patients. Amgen said patients treated with Kyprolis lived for a median of 26.3 months without disease worsening, a significant improvement compared to the 17.6 months in patients who received standard treatment.

Chief Executive Robert Bradway said "Our mission at Amgen is to serve patients by advancing medicines that address serious disease. Kyprolis is an important building block in our robust, differentiated pipeline."

AMGN is currently trading at $126.84, up $1.29 or 1.03%, on the Nasdaq.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Bank of Nova Scotia or otherwise known as Scotiabank, Friday reported lower net profit for the third quarter, in the absence of a year-ago gain. Earnings per share, however, came in line with the Street view. Further, the company said it raised its quarterly dividend by 2 cents. Non-traditional discount and variety stores operator Big Lots Inc. (BIG) Friday reported a decline in net profit for the second quarter, while net sales grew 1.2 percent from the prior year. Comparable sales for the quarter increased 2.8 percent. Google has rejected the European Union's charges that it abused its market power and the demanded that it change the way it ranks online comparison shopping services in its search results, setting up a potentially long legal battle with the EU regulator empowered to levy billions of euros in fines
comments powered by Disqus
RELATED NEWS
Trade AMGN now with 
Follow RTT